AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: Pirtobrutinib is a non-covalent BTKi with significant therapeutic efficacy as continuous monotherapy and in time-limited combined targeted regimens in both treatment-naïve and relapsed/refractory (R/R) CLL. The BRUIN-CLL-322 trial demonstrated improved outcomes for patients (pts) with R/R CLL treated with fixed-duration Pirtobrutinib+Venetoclax+Rituximab versus Venetoclax+Rituximab, including in pts previously treated with covalent BTKi (cBTKi) (Davids M, Lancet 2026). Given the safety and efficacy of pirtobrutinib in R/R CLL and the high response rate reported with triple combinations of cBTKi, venetoclax and CD20 mAb in R/R CLL (Rogers K, Blood 2018, Furstenau M, Blood 2024), we investigated the activity and safety of combined time-limited pirtobrutinib with venetoclax and obinutuzumab (PVO) for pts with R/R CLL.
Methods: This is an ongoing Investigator-initiated Phase II trial of time-limited PVO as treatment of pts with R/R CLL (NCT06967610). Prior exposure to cBTKi and BCL2-inhibitors (BCL2i) was allowed. Pts with R/R CLL and treatment indications according to 2018 iwCLL criteria received pirtobrutinib 200mg daily starting Cycle 1 Day 1 (C1D1) continuously until end of C25. Standard 6 cycles obinutuzumab started C1D1. Venetoclax standard ramp-up initiated C2D1 to the target 400mg daily dose and continued until end of C25. Each cycle is 28 days. Study endpoints are 2018 iwCLL responses, rates of bone marrow uMRD4 and uMRD6, safety and tolerability of the combination. Response evaluations (iwCLL 2018 criteria) included bone marrow flow cytometry and next-generation sequencing (ClonoSEQ assay) at the end of C7, C13, C19 and C25. Tumor lysis syndrome (TLS) risk assessment was performed at study entry.
Results: Between July 2025 and July 2026 32 pts were enrolled, we report on the first 20 pts evaluable for response and toxicity having reached C7 or beyond. Median age is 66 years (range, 41-80), 9 (45%) pts are ≥70 years, 12 (60%) pts are male. Median number of prior treatments is 2 (range 1-4), 18 (90%) pts had prior treatment with targeted therapies: cBTKi, 14 (70%) pts, BCL2-inhibitor 10 (50%) pts, anti-CD20 mAb 15 (75%) pts and combined ibrutinib plus venetoclax 4 (20%) pts. Fifteen (75%) pts had IGHV-unmutated CLL, FISH analysis showed del(17p) in 4 (20%) pts, del(11q) in 4 (20%) pts, TP53 mutation in 8 (40%) pts and complex karyotype (≥3 abnormalities) in 4 (20%) pts. NGS testing at study entry revealed that 4 (20%) pts had BTK mutations and one (5%) pt had a BCL2 mutation. At the time of treatment initiation 6 (30%) pts had Rai III-IV stage disease. Maximum lymph node dimension was ≥5 cm in 4 (20%) pts.
The median follow-up for all pts is 8 months (range 5.5-11). All 20 pts completed C7 (1st response assessment) and 5 pts have also completed C13 (2nd response assessment).
All 20 evaluable pts responded by 2018 iwCLL response criteria, (OR 100%), 14 pts (70%) achieved CR and 6 (30%) PR, uMRD4 rates in blood and bone marrow were 75% and 65%,
respectively, uMRD6 (including sequences detected below limit of detection) rates in blood and bone marrow were 40% and 25%, respectively.
The most common toxicities observed were Grade 3-4 neutropenia and thrombocytopenia occurring in 10 (50%) and 4 (20%) of pts, respectively. Grade 3-4 infectious episodes were observed in 2 (10%) pts, one pt with prior h/o of atrial fibrillation developed recurrent atrial fibrillation (Grade 2) during C9 and remains on study. One pt with prior history of severe reactions to rituximab could not tolerate obinutuzumab and continues treatment with PV only. Dose modifications (dose, reductions, delays and omission) were needed in 5 (25%) pts.
All patients are alive and continuing treatment.
Conclusions: We report early results of our ongoing trial of combined PVO in pts with R/R CLL. We observed high rates of clinical response and achievement of uMRD in both PB and BM, including in pts previously treated with targeted agents. The treatment was well tolerated with a favorable benefit-risk profile. Accrual to this study is ongoing, additional pts and updated results will be presented at the meeting.
DISCLOSURES
Alessandra Ferrajoli III, MD: Genentech - Honoraria; BeOne Medicines, Ltd - Honoraria; AstraZeneca - Honoraria; AbbVie - Research Funding; Eli-Lilly - Research Funding